Medication Cost is Significantly Reduced After Roux-en-Y Gastric Bypass in Obese Patients
Authors:
- Ina GesquiereIGIna Gesquiere
- Judith Aron-WisnewskyJAJudith Aron-Wisnewsky
- Veerle FoulonVFVeerle Foulon
- Steeve HaggegeSHSteeve Haggege
- Bart Van der SchuerenBSBart Van der Schueren
- Patrick AugustijnsPAPatrick Augustijns
- Jean-Luc BouillotJBJean-Luc Bouillot
- Karine ClementKCKarine Clement
- Arnaud BasdevantABArnaud Basdevant
- Jean-Michel OppertJOJean-Michel Oppert
- Marion BuyseMBMarion Buyse
- 20 June 2014
- journal article
- research article
- Published by Springer Nature in Obesity Surgery
- Vol. 24 (11) , 1896-1903
Abstract
Background This study aims to determine the influence of Roux-en-Y gastric bypass (RYGB) on medication-related costs. Methods The study analyzed the types, dosages, and costs of drugs and medical devices prescribed before and after surgery (1, 3, 6, and 12 months and yearly thereafter) in patients who underwent RYGB between June 2004 and May 2010 and had an outpatient visit between December 2009 and May 2010 at Pitié-Salpêtrière University Hospital, Paris, France. Results The cohort included 143 patients (78 % female; mean age, 42.9 years; mean BMI, 48.6 kg/m2). Total prescription costs were significantly lower (−32 %, p < 0.001) 1 year after RYGB compared with preoperative costs. However, the cost for medications to prevent RYGB side effects (in particular nutritional deficiencies) displayed a 36-fold increase in the first month postsurgery, but then decreased progressively over time. Importantly, the cost related to the treatment of the two most frequent obesity-related diseases significantly decreased 1 year after surgery. Indeed, prescription costs for treatment of type 2 diabetes (T2D) and obstructive sleep apnea (OSA) (namely CPAP therapy considered as the gold standard treatment) were reduced 1 year after surgery by 85 and by 63 % (both p < 0.001), respectively. We also observed a trend toward a decrease in the prescription costs of other obesity-related diseases, although it did not reach significance in our cohort. Conclusions Considering medication to treat both obesity-related diseases and prevention of secondary effects of bariatric surgery, we observed that overall postoperative medication costs were significantly reduced one year after surgery, especially for T2D and OSA.Keywords
This publication has 42 references indexed in Scilit:
- Surgical vs Conventional Therapy for Weight Loss Treatment of Obstructive Sleep ApneaJAMA, 2012
- Mechanisms of improved glycaemic control after Roux-en-Y gastric bypassDiabetologia, 2012
- Surgical approaches to the treatment of obesityNature Reviews Gastroenterology & Hepatology, 2011
- Cardiovascular benefits of bariatric surgery in morbidly obese patientsObesity Reviews, 2011
- The therapeutics of lifestyle management on obesityDiabetes, Obesity and Metabolism, 2010
- Management of gallstones and gallbladder disease in patients undergoing gastric bypassWorld Journal of Gastroenterology, 2010
- Two Year Reduction In Sleep Apnea Symptoms and Associated Diabetes Incidence After Weight Loss In Severe ObesitySLEEP, 2007
- Nutritional deficiency after gastric bypass: diagnosis, prevention and treatmentDiabetes & Metabolism, 2007
- Loss of Insulin Resistance after Roux-en-Y Gastric Bypass Surgery: a Time Course StudyObesity Surgery, 2005
- Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference StatementThe American Journal of Clinical Nutrition, 1992